Does Ozempic Cause Macular Degeneration? What the Latest Studies Actually Found
The Short Answer About Ozempic and Macular Degeneration
No study has shown that Ozempic causes macular degeneration. A few studies have looked at whether the drug is linked to the wet form of age-related macular degeneration (AMD), and the results do not agree. One large study of older adults with diabetes linked GLP-1 drugs, almost all of them semaglutide, to a small rise in new wet AMD1. A separate large study found no such difference in wet AMD risk with semaglutide2. A link seen in one study is not proof of cause.
Much of the news about Ozempic and the eyes is not about the macula at all. Recent studies have most closely tied semaglutide to a raised risk of NAION3. NAION is caused by reduced blood flow to the optic nerve, not the macula4. The optic nerve and the macula are different parts of the eye, so it is easy to mix up these two stories. This page keeps them separate.
If you take Ozempic, this is a reason to keep up with eye checks and to raise any vision change with your care team, not a reason to stop your medicine on your own. Ozempic is prescribed for real reasons, such as blood sugar or weight, and stopping it has its own risks. The sections below walk through what each study found, how strong the evidence is, and which eye symptoms are worth a prompt call.
What Ozempic and Macular Degeneration Actually Are
Ozempic is a brand name for semaglutide, a medicine in the GLP-1 receptor agonist family. It is given as a weekly injection and is used to help manage type 2 diabetes, and related semaglutide products are used for weight management. Understanding that Ozempic is semaglutide matters here, because the eye studies are written about semaglutide and the wider GLP-1 group, not the brand name.
Age-related macular degeneration affects the macula, the central part of the retina, and most people have the dry form while the less common wet form usually causes faster vision loss5. The wet form, also called neovascular AMD, is the type the semaglutide studies focused on. It involves abnormal blood vessels under the retina, and it is the form doctors most want to catch early.
NAION happens when blood flow to the optic nerve drops, and it usually causes sudden, painless vision loss in one eye4. Because it involves the optic nerve, not the macula, NAION is not a form of macular degeneration. Headlines about Ozempic and vision often describe NAION, so it helps to know the two conditions are separate even though both involve the eye.
What the Latest Studies Actually Found
The main study behind the macular degeneration question looked back at health records in Ontario, Canada. Among adults with diabetes aged 66 and older, about 2 in 1,000 who took a GLP-1 drug developed wet AMD over 3 years, compared with about 1 in 1,000 who did not, an adjusted hazard ratio of 2.211. In that study, almost everyone taking a GLP-1 drug was on semaglutide, so the finding is really about semaglutide.
A different, larger analysis reached the opposite conclusion. A multi-database network study detected no difference in the risk of wet AMD between people taking semaglutide and those taking other diabetes drugs2. When two careful studies disagree, the honest summary is that a link is possible but not settled, which is very different from saying the drug causes the disease.
The optic-nerve studies are worth understanding because they are often mixed into the same conversation. In one cohort of people with diabetes, semaglutide was associated with a higher risk of NAION, with a hazard ratio of about 4.28, though the researchers noted the absolute risk is likely quite low3. This is a signal about the optic nerve, and it does not tell us anything about the macula.
How Strong Is the Evidence?
Every study here is observational, meaning researchers looked back at records of people who happened to take these drugs rather than assigning treatments in a trial. The authors of the wet-AMD study say further study is needed to confirm their findings1. Observational studies can spot a link, but they cannot prove that one thing caused the other, because other differences between the groups may explain what is seen.
The two wet-AMD studies do not agree, and that disagreement is itself important information. The larger network study found no difference in wet AMD risk between semaglutide and other diabetes drugs2. When findings conflict like this, scientists usually wait for more and better data before drawing a firm conclusion, and no major guideline currently says Ozempic causes macular degeneration.
Even in the study that found a link, the difference was small in absolute terms. Going from about 1 in 1,000 to about 2 in 1,000 over 3 years is a real difference worth studying, but it still means the large majority of people did not develop wet AMD. Relative numbers like 'twice the risk' can sound alarming until you see the small everyday numbers behind them.
What This Means for You If You Take Ozempic
The most important takeaway is a practical one. Ozempic is prescribed to manage conditions that carry their own serious risks, and stopping it without medical advice can allow those conditions to worsen. If a possible eye risk worries you, the right move is a conversation with the doctor who prescribes it and your eye doctor, who can weigh your personal risks together, rather than a decision made alone.
Regular eye care is the best tool for catching AMD early, whether or not you take Ozempic. Wet AMD usually causes faster vision loss than dry AMD, which is why early detection matters5. Tell your eye doctor which medicines you take, mention any family history of macular degeneration, and ask how often you should be seen based on your own risk.
For most people taking Ozempic, the current evidence does not point to a large eye risk, and the absolute numbers in these studies are small. Research is active and the picture may change as better studies arrive. Staying informed, keeping your eye appointments, and reporting new vision changes promptly is a steady, sensible plan while the science continues to develop.
Eye Symptoms That Mean You Should Call
Some eye changes should not wait. NAION typically causes sudden, painless loss of vision in one eye4. If you lose vision suddenly, especially in one eye and without pain, contact an eye doctor or seek urgent care right away, because a fast evaluation is what protects the vision you still have. Do not assume painless means minor.
Changes that point toward wet AMD also deserve a prompt call. If straight lines suddenly look wavy or crooked, or a new blurry or blank spot appears near the center of your vision, reach out to your eye doctor within a day or two rather than waiting. Wet AMD is treatable, and starting treatment sooner helps preserve central vision.
For ongoing care, a comprehensive eye exam is the place these concerns are sorted out. Wet AMD is managed by a retina specialist, whom your general eye doctor can refer you to if needed. If you take Ozempic and simply want reassurance, book a routine exam and bring your medication list rather than waiting for a symptom to appear.
Common Questions About Ozempic and Your Eyes
No. No study has shown that Ozempic causes macular degeneration. One study linked GLP-1 drugs, almost all semaglutide, to a small rise in wet AMD in older adults with diabetes, but another large study found no difference from other diabetes drugs. These are observational studies that can find a link but cannot prove cause. The honest summary today is that a possible association is being studied, not that the drug causes the disease.
Usually not. Most of the coverage is about NAION, a condition of the optic nerve that can cause sudden, painless vision loss in one eye. NAION is not macular degeneration, which affects the macula in the retina. Both involve the eye, so the stories get blended together, but they are different conditions studied in different papers. It helps to check which one an article is actually describing.
In the study that found a link, the difference was small in everyday terms. About 2 in 1,000 people on a GLP-1 drug developed wet AMD over 3 years, compared with about 1 in 1,000 who did not1. That is roughly double in relative terms but still a small number, and most people did not develop AMD. A separate large study found no difference at all, so the true risk, if any, is not yet settled.
That is a decision for you and your prescriber, not something to act on alone after reading a study. The evidence on eye risk is limited and mixed, while the benefit you get from the medicine is usually well established for your own condition. Bring your specific worry to the appointment, ask how the possible eye findings apply to you, and let your prescriber and eye doctor weigh both sides before any change is made.
More Questions, and What to Ask Your Doctor
Call promptly for sudden, painless vision loss in one eye, which can be a sign of a NAION-type optic nerve problem. Also call within a day or two if straight lines suddenly look wavy, or a new blurry or dark spot appears near the center of your vision, which can point toward wet AMD. Both are far more treatable when checked early, so it is better to be seen than to wait.
There is no special mandatory test just for taking Ozempic. The best step is a regular comprehensive eye exam, where your eye doctor can check your macula and optic nerve and note any changes over time. Tell them you take semaglutide and share any family history of eye disease. Based on your own risk factors, they can decide how often you should be seen.
Quite possibly. The current evidence is observational and conflicting, which is exactly the situation where new, stronger studies can shift the picture in either direction. Researchers are actively studying GLP-1 drugs and eye health. Until clearer results arrive, the responsible summary is that a link is possible but unproven, and decisions about your medicine should be made with your doctors rather than on your own.
- Given my health history, do you think the current eye findings change anything for me?
- How often should I have a comprehensive eye exam while taking Ozempic?
- What eye symptoms should make me call you right away versus wait for a routine visit?
- Do I have any risk factors for wet AMD or for NAION that I should know about?
- If I am worried, is there a reason to change or continue my medication?
- American Academy of Ophthalmology (Editors' Choice) (2025). Exposure to GLP-1 RAs May Increase the Risk of New-Onset Neovascular AMD.
- Ophthalmology Science / OHDSI network study (PMC) (2025). Semaglutide and Neovascular Age-Related Macular Degeneration Among Adults with Type 2 Diabetes: An OHDSI Network Study.
- American Academy of Ophthalmology (Editors' Choice) (2025). Semaglutide May Be Associated With an Increased Risk of Developing NAION.
- Cleveland Clinic (2023). Anterior Ischemic Optic Neuropathy (AION).
- National Eye Institute (NEI) (2024). Age-Related Macular Degeneration.